{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"VVOAZFWZEDHOOU-UHFFFAOYSA-N","prefName":"magnolol","symbol":"magnolol","iupacName":"2-(2-hydroxy-5-prop-2-enylphenyl)-4-prop-2-enylphenol","aliases":["Magnoliol","5,5'-Diallyl-2,2'-dihydroxybiphenyl","Dehydrodichavicol","4-allyl-2-(5-allyl-2-hydroxy-phenyl)phenol"],"cas":"528-43-8","pubchemCid":"72300","chebiId":"CHEBI:6643","smiles":"C=CCC1=CC(=C(C=C1)O)C2=C(C=CC(=C2)CC=C)O","molecularFormula":"C18H18O2","molecularWeight":266.3,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/72300","chebi":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:CHEBI:6643"}},"classification":{"family":"ecs_tool","familyLabel":"ECS modulator (research)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (research tool)","summaryFr":"Biosynthetic pathway: magnolol is a biphenyl neolignan. The enzymatic details of its formation are not described in the sources consulted.","originNote":"Main constituent of the bark of Magnolia officinalis (Li et al., 2020), known as houpo and used in traditional Chinese medicine (Zhao et al., 2026). It has also been isolated from Magnolia grandiflora seeds (Pandey et al., 2023).","discovered":""},"pharmacology":{"summaryFr":"Magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) is a biphenyl neolignan and the main constituent of the bark of Magnolia officinalis. Rempel et al. (2012) described its activity at cannabinoid receptors: a CB2-selective partial agonism with an EC50 of 3.28 µM in a cAMP assay, while its reduced metabolite, tetrahydromagnolol, proved more potent (EC50 of 0.170 µM). Pandey et al. (2023) report a Ki of 1.4 µM at CB2 and of 17.82 µM at CB1, by radioligand displacement. Yip et al. (2025), by contrast, observed no specific activity at either receptor in fluorescence assays, while describing an effect on T-type calcium channels and an antiseizure activity in mice. These results, obtained with different methods, do not yet allow a cannabinoid activity to be firmly established.","receptorSummaryFr":"Magnolol has been reported as a weak ligand of the CB2 receptor, with results that differ by method. In radioligand displacement, Pandey et al. (2023) measure a Ki of 1.4 µM at CB2 and of 17.82 µM at CB1, with selectivity for CB2. In a cAMP functional assay, Rempel et al. (2012) describe a CB2-selective partial agonist with an EC50 of 3.28 µM, and a reduced metabolite, tetrahydromagnolol, which is more potent (EC50 of 0.170 µM). Fuchs et al. (2013) also describe partial activity at CB1, with an EC50 of 18.3 µM in a similar assay. In fluorescence assays, Yip et al. (2025) observe no specific activity at CB1 or CB2.","binding":[{"target":"CB2","efficacy":"partial_agonist","relativeActivity":37,"reported":"Ki 1,4 µM (Pandey et coll., 2023) ; CE50 3,28 µM en AMPc, agoniste partiel (Rempel et coll., 2012) ; aucune activité spécifique en fluorescence (Yip et coll., 2025)","confidence":"medium"},{"target":"CB1","efficacy":"modulator","relativeActivity":5,"reported":"Ki 17,82 µM (Pandey et coll., 2023) ; CE50 18,3 µM en AMPc, activité partielle (Fuchs et coll., 2013) ; aucune activité spécifique en fluorescence (Yip et coll., 2025)","confidence":"medium"}],"references":[{"label":"Pandey et coll., néolignanes de Magnolia grandiflora contre les récepteurs cannabinoïdes et opioïdes, Molecules 2023","pmid":"36770918","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/36770918/"},{"label":"Rempel et coll., extrait de magnolia, magnolol et métabolites : activation des récepteurs CB2 et blocage du GPR55, ACS Medicinal Chemistry Letters 2012","pmid":"24900561","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/24900561/"},{"label":"Fuchs et coll., le magnolol, structure de départ d'agonistes puissants des récepteurs cannabinoïdes, PLoS One 2013","pmid":"24204944","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/24204944/"},{"label":"Yip et coll., molécules de type cannabinoïde issues de plantes non cannabiques et activité antiépileptique chez la souris, Epilepsia 2025","pmid":"39530840","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/39530840/"},{"label":"Zhao et coll., blocage du canal hERG par le magnolol et l'honokiol, Toxicology Letters 2026","pmid":"42392381","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/42392381/"},{"label":"Kim et coll., modulation de l'activité CYP1A et CYP2C hépatique du rat par l'honokiol et le magnolol, Molecules 2018","pmid":"29914211","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/29914211/"},{"label":"Xie et coll., sulfatation du magnolol et effet sur son activité, Metabolites 2022","pmid":"36144273","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/36144273/"},{"label":"Ding et coll., micelles mixtes et biodisponibilité orale du magnolol, Artificial Cells, Nanomedicine, and Biotechnology 2018","pmid":"30183380","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/30183380/"},{"label":"Li et coll., micelles et nanosuspensions pour la biodisponibilité orale du magnolol, Drug Delivery 2020","pmid":"32631085","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/32631085/"},{"label":"Jiang et coll., contrôle qualité de l'écorce de Magnolia officinalis par RMN du proton et CLHP, Phytochemical Analysis 2012","pmid":"22025447","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/22025447/"},{"label":"Schifano et coll., potentiel de détournement des composés de Magnolia officinalis, Human Psychopharmacology 2017","pmid":"28517911","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/28517911/"},{"label":"Oflaz et Turan, extrait d'écorce de Magnolia officinalis et syndrome métabolique chez le rat, Biochemical Genetics 2026","pmid":"40986232","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/40986232/"},{"label":"PubChem CID 72300 : magnolol (identifiants et masse moléculaire)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/72300"},{"label":"ANSM, liste consolidée des stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (substances des tableaux de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":20},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":10},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":15},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":5},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":10}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"unscheduled","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure has been identified in the sources consulted: any control would fall under the national law of each member state.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"It is not listed on the consolidated list of narcotics published by the ANSM (update of 16 February 2026), and its structure meets none of the generic family definitions in that list: it has no cyclohexyl ring (cyclohexylphenols), no indole, indazole, pyrrole, indene, thiazole or benzo[c]chromene nucleus, and it is not a tetrahydrocannabinol.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Pandey et coll., néolignanes de Magnolia grandiflora contre les récepteurs cannabinoïdes et opioïdes, Molecules 2023","pmid":"36770918","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/36770918/"},{"label":"Rempel et coll., extrait de magnolia, magnolol et métabolites : activation des récepteurs CB2 et blocage du GPR55, ACS Medicinal Chemistry Letters 2012","pmid":"24900561","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/24900561/"},{"label":"Fuchs et coll., le magnolol, structure de départ d'agonistes puissants des récepteurs cannabinoïdes, PLoS One 2013","pmid":"24204944","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/24204944/"},{"label":"Yip et coll., molécules de type cannabinoïde issues de plantes non cannabiques et activité antiépileptique chez la souris, Epilepsia 2025","pmid":"39530840","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/39530840/"},{"label":"Zhao et coll., blocage du canal hERG par le magnolol et l'honokiol, Toxicology Letters 2026","pmid":"42392381","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/42392381/"},{"label":"Kim et coll., modulation de l'activité CYP1A et CYP2C hépatique du rat par l'honokiol et le magnolol, Molecules 2018","pmid":"29914211","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/29914211/"},{"label":"Xie et coll., sulfatation du magnolol et effet sur son activité, Metabolites 2022","pmid":"36144273","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/36144273/"},{"label":"Ding et coll., micelles mixtes et biodisponibilité orale du magnolol, Artificial Cells, Nanomedicine, and Biotechnology 2018","pmid":"30183380","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/30183380/"},{"label":"Li et coll., micelles et nanosuspensions pour la biodisponibilité orale du magnolol, Drug Delivery 2020","pmid":"32631085","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/32631085/"},{"label":"Jiang et coll., contrôle qualité de l'écorce de Magnolia officinalis par RMN du proton et CLHP, Phytochemical Analysis 2012","pmid":"22025447","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/22025447/"},{"label":"Schifano et coll., potentiel de détournement des composés de Magnolia officinalis, Human Psychopharmacology 2017","pmid":"28517911","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/28517911/"},{"label":"Oflaz et Turan, extrait d'écorce de Magnolia officinalis et syndrome métabolique chez le rat, Biochemical Genetics 2026","pmid":"40986232","doi":null,"url":"https://pubmed.ncbi.nlm.nih.gov/40986232/"},{"label":"PubChem CID 72300 : magnolol (identifiants et masse moléculaire)","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/72300"},{"label":"ANSM, liste consolidée des stupéfiants, mise à jour du 16 février 2026","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"INCB, Green List 2026 (substances des tableaux de la Convention de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}],"meta":{"slug":"magnolol","url":"https://en.phytogrammes.com/wiki/magnolol","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}